A phase II irinotecan–cisplatin combination in advanced pancreatic cancer

We report a cisplatin and irinotecan combination in patients with biopsy-proven advanced pancreatic adenocarcinoma. Patients were selected from a specialist centre and required good performance status (KPS>70%), measurable disease on CT scan, and biochemical and haematological parameters within n...

Descripción completa

Detalles Bibliográficos
Autores principales: Markham, C, Stocken, D D, Hassan, A B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394443/
https://www.ncbi.nlm.nih.gov/pubmed/14612893
http://dx.doi.org/10.1038/sj.bjc.6601377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394443/
https://www.ncbi.nlm.nih.gov/pubmed/14612893
http://dx.doi.org/10.1038/sj.bjc.6601377

Ejemplares similares